Fig. 3From: Circulating tumor cells and palbociclib treatment in patients with ER-positive, HER2-negative advanced breast cancer: results from a translational sub-study of the TREnd trialPFS according to T1-T0 change. “increase” category when nCTCs T1 – nCTCsT0 > 3, “no increase” category when nCTCs T1 – nCTCs T0 < 3Back to article page